

Lutz Frankenstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1060623/publications.pdf>

Version: 2024-02-01

74
papers

1,925
citations

279798

23
h-index

289244

40
g-index

74
all docs

74
docs citations

74
times ranked

3533
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	3.3	22
2	Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study. <i>Clinical Research in Cardiology</i> , 2022, 111, 333-342.	3.3	4
3	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	3.9	26
4	Impact of the introduction of percutaneous edge-to-edge mitral valve reconstruction on clinical practice in Germany compared to surgical valve repair. <i>Clinical Research in Cardiology</i> , 2021, 110, 620-627.	3.3	1
5	Temporary oral anticoagulation after MitraClip â€œ a strategy to lower the incidence of post-procedural stroke?. <i>Acta Cardiologica</i> , 2020, 75, 61-67.	0.9	11
6	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2020, 25, 161-171.	3.9	8
7	The chameleon of cardiology: cardiac sarcoidosis before and after heart transplantation. <i>ESC Heart Failure</i> , 2020, 7, 692-696.	3.1	10
8	An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK. <i>Journal of Medical Economics</i> , 2020, 23, 1425-1434.	2.1	12
9	The role of diabetes in cardiomyopathies of different etiologiesâ€”Characteristics and 1-year follow-up results of the EVITA-HF registry. <i>PLoS ONE</i> , 2020, 15, e0234260.	2.5	2
10	Cross-lagged analyses of the bidirectional relationship between depression and markers of chronic heart failure. <i>Depression and Anxiety</i> , 2020, 37, 898-907.	4.1	8
11	N-terminal pro brain natriuretic peptide eliminates the prognostic effect of atrial fibrillation in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2019, 6, 640-648.	3.1	2
12	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure â€œ A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019, 289, 83-90.	1.7	10
13	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2019, 156, 706-714.	0.8	33
14	Long-term biological variation of high-sensitivity cardiac troponin T using minimal important differences and reference change values in stable outpatients with cardiovascular disease. <i>Clinical Biochemistry</i> , 2019, 67, 7-11.	1.9	7
15	READY: relative efficacy of loop diuretics in patients with chronic systolic heart failureâ€œa systematic review and network meta-analysis of randomised trials. <i>Heart Failure Reviews</i> , 2019, 24, 461-472.	3.9	14
16	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019, 105, 1252-1259.	2.9	18
17	Unidimensional Longitudinal Strain: A Simple Approach for the Assessment of Longitudinal Myocardial Deformation by Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 733-742.	2.8	8
18	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. <i>Clinical Research in Cardiology</i> , 2018, 107, 460-470.	3.3	29

#	ARTICLE	IF	CITATIONS
19	Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment. <i>Acta Cardiologica</i> , 2018, 73, 378-386.	0.9	12
20	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 611-618.	0.6	66
21	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 82-92.	3.0	11
22	The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. <i>European Journal of Health Economics</i> , 2018, 19, 223-228.	2.8	9
23	Anxiety and self-care behaviour in patients with chronic systolic heart failure: A multivariate model. <i>European Journal of Cardiovascular Nursing</i> , 2018, 17, 170-177.	0.9	52
24	Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. <i>Clinical Research in Cardiology</i> , 2018, 107, 1040-1049.	3.3	10
25	Volumeâ€“outcome relationship in transcatheter aortic valve implantations in Germany 2008â€“2014: a secondary data analysis of electronic health records. <i>BMJ Open</i> , 2018, 8, e020204.	1.9	22
26	Haemodynamic effects of percutaneous mitral valve edgeâ€“toâ€“edge repair in patients with endâ€“stage heart failure awaiting heart transplantation. <i>ESC Heart Failure</i> , 2018, 5, 892-901.	3.1	20
27	The need for dedicated advanced heart failure units to optimize heart failure care: impact of optimized advanced heart failure unit care on heart transplant outcome in highâ€“risk patients. <i>ESC Heart Failure</i> , 2018, 5, 1108-1117.	3.1	21
28	Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome. <i>PLoS ONE</i> , 2018, 13, e0202133.	2.5	15
29	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 711-721.	3.3	27
30	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. <i>ESC Heart Failure</i> , 2017, 4, 66-70.	3.1	2
31	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	1.7	5
32	Learning Curves Among All Patients Undergoing Transcatheter Aortic Valve Implantation in Germany: A Retrospective Observational Study. <i>International Journal of Cardiology</i> , 2017, 235, 17-21.	1.7	20
33	Hemodynamic Determinants of the Biologic Variation of N-Terminal Proâ€“B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 835-842.	1.7	3
34	Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 974-985.	3.3	9
35	Predicting hospitalization and mortality in patients with heart failure: The BARDICHE-index. <i>International Journal of Cardiology</i> , 2017, 227, 901-907.	1.7	8
36	Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. <i>PLoS ONE</i> , 2017, 12, e0187662.	2.5	48

#	ARTICLE	IF	CITATIONS
55	Minimal important difference for 6-minute walk test distances among patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 94-98.	1.7	51
56	Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2013, 102, 771-780.	3.3	9
57	Conversion to generic cyclosporine A in stable chronic patients after heart transplantation. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1421.	4.3	6
58	Influence of Sex on Treatment and Outcome in Chronic Heart Failure. <i>Cardiovascular Therapeutics</i> , 2012, 30, 182-192.	2.5	17
59	A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. <i>Clinical Research in Cardiology</i> , 2012, 101, 1-10.	3.3	29
60	Biological variation of high sensitive Troponin T in stable heart failure patients with ischemic or dilated cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2011, 100, 633-640.	3.3	24
61	Biological Variation and Reference Change Value of High-Sensitivity Troponin T in Healthy Individuals during Short and Intermediate Follow-up Periods. <i>Clinical Chemistry</i> , 2011, 57, 1068-1071.	3.2	115
62	The Difficult Task of Finding the Best Antihypertensive Agent. <i>Archives of Internal Medicine</i> , 2011, 171, 394-5.	3.8	1
63	The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. <i>European Journal of Heart Failure</i> , 2010, 12, 574-580.	7.1	30
64	The obesity paradox in stable chronic heart failure does not persist after matching for indicators of disease severity and confounders. <i>European Journal of Heart Failure</i> , 2009, 11, 1189-1194.	7.1	35
65	Prevalence and prognostic significance of adrenergic escape during chronic β -blocker therapy in chronic heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 178-184.	7.1	11
66	Validity, prognostic value and optimal cutoff of respiratory muscle strength in patients with chronic heart failure changes with beta-blocker treatment. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 424-429.	2.8	29
67	Variability of N-Terminal Probrain Natriuretic Peptide in Stable Chronic Heart Failure and Its Relation to Changes in Clinical Variables. <i>Clinical Chemistry</i> , 2009, 55, 923-929.	3.2	25
68	Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure. <i>Basic Research in Cardiology</i> , 2009, 104, 731-738.	5.9	18
69	Respiratory muscle function and exercise intolerance in heart failure. <i>Current Heart Failure Reports</i> , 2009, 6, 95-101.	3.3	103
70	Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials. <i>Clinical Research in Cardiology</i> , 2008, 97, 594-600.	3.3	9
71	Sex-specific Predictive Power of 6-Minute Walk Test in Chronic Heart Failure Is Not Enhanced Using Percent Achieved of Published Reference Equations. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 427-434.	0.6	6
72	Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. <i>European Heart Journal</i> , 2008, 29, 2634-2640.	2.2	35

#	ARTICLE	IF	CITATIONS
73	Is serial determination of inspiratory muscle strength a useful prognostic marker in chronic heart failure?. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 156-161.	2.8	17
74	Beta-Blockers Influence the Short-term and Long-term Prognostic Information of Natriuretic Peptides and Catecholamines in Chronic Heart Failure Independent From Specific Agents. Journal of Heart and Lung Transplantation, 2007, 26, 1033-1039.	0.6	10